tipifarnib has been researched along with sorafenib in 10 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 6,520 | 730 | 5,251 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Korzeniecki, C; Priefer, R | 1 |
| Chintala, L; El Naggar, AK; Gagel, R; Hong, D; Kurzrock, R; Wright, J; Ye, L | 1 |
| Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ | 1 |
| Blaskovich, MA; El Naggar, AK; Gagel, RF; Hong, DS; Khan, R; Kurzrock, R; Moulder, S; Naing, A; Newman, RA; Ng, CS; Sebti, SM; Sherman, SI; Tannir, NM; Trent, J; Wheler, JJ; Wright, JJ; Ye, L | 1 |
| Le Moulec, S; Loriot, Y; Soria, JC | 1 |
| Bidyasar, S; Busaidy, NL; Cabanillas, ME; El Naggar, AK; Hernandez, M; Hong, DS; Kurzrock, R; Naing, A; Sherman, SI; Tsimberidou, AM; Waguespack, SG; Wheler, J; Wright, J; Ye, L | 1 |
| Akerley, WL; Flaherty, LE; Kirkwood, JM; Lao, CD; Margolin, KA; Moon, J; Othus, M; Sondak, VK; Sosman, JA | 1 |
| Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J | 1 |
| Abrey, LE; Aldape, K; Chang, S; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Ebiana, VA; Gilbert, M; Kuhn, J; Levin, VA; Lieberman, F; Mehta, MP; Nghiemphu, PL; Prados, M; Robins, HI; Wen, P; Wright, JJ; Yung, WKA | 1 |
1 review(s) available for tipifarnib and sorafenib
| Article | Year |
|---|---|
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2021 |
5 trial(s) available for tipifarnib and sorafenib
| Article | Year |
|---|---|
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Treatment Outcome | 2009 |
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Neuroendocrine; Cell Differentiation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Female; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Niacinamide; Oncogene Protein p21(ras); Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; raf Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2011 |
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome | 2012 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid | 2013 |
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Sorafenib; Treatment Outcome | 2018 |
4 other study(ies) available for tipifarnib and sorafenib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Cell Line, Tumor; Exons; Humans; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Thyroid Neoplasms | 2008 |
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2008 |
[Targeting KRAS pathway in NSCLC therapy].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib | 2009 |